References
- Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008 27:5904-12; PMID:18836471; http://dx.doi.org/10.1038/onc.2008.271
- Tsukishiro T, Donnenberg AD, Whiteside TL. Rapid turnover of the CD8(+)CD28(-) T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother 2003 52:599-607; PMID:12827303; http://dx.doi.org/10.1007/s00262-003-0395-6
- Mondal AM, Horikawa I, Pine SR, Fujita K, Morgan KM, Vera E, Mazur SJ, Appella E, Vojtesek B, Blasco MA, Lane DP, Harris CC. p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest 2013 123:5247-57; PMID:24231352; http://dx.doi.org/10.1172/JCI70355
- Effros RB, Dagarag M, Spaulding C, Man J. The role of CD8+ T-cell replicative senescence in human aging. Immunol Rev 2005 205:147-57; PMID:15882351; http://dx.doi.org/10.1111/j.0105-2896.2005.00259.x
- Ye J, Huang X, Hsueh EC, Zhang Q, Ma C, Zhang Y, Varvares MA, Hoft DF, Peng G. Human regulatory T cells induce T-lymphocyte senescence. 2012 Blood 120:2021-31; PMID:22723548; http://dx.doi.org/10.1182/blood-2012-03-416040
- Ye J, Ma C, Hsueh EC, Eickhoff CS, Zhang Y, Varvares MA, Hoft DF, Peng G. Tumor-derived gammadelta regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J Immunol 2013 190:2403-14; PMID:23355732; http://dx.doi.org/10.4049/jimmunol.1202369
- Ye J, Ma C, Hsueh EC, Dou J, Mo W, Liu S, Han B, Huang Y, Zhang Y, Varvares MA, Hoft DF, Peng G. TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence. EMBO Mol Med 2014 6:1294-311; PMID:25231413; http://dx.doi.org/10.15252/emmm.201403918
- Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 2008 14:5947-52; PMID:18829471; http://dx.doi.org/10.1158/1078-0432.CCR-08-0229
- Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007 7:880-7; PMID:17957190; http://dx.doi.org/10.1038/nrc2250
- Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, Wang DY, Li Y, Wang HY, Wang RF. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005 309:1380-4; PMID:16123302; http://dx.doi.org/10.1126/science.1113401